These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 35449580)

  • 1. CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.
    Elmas E; Saljoughian N; de Souza Fernandes Pereira M; Tullius BP; Sorathia K; Nakkula RJ; Lee DA; Naeimi Kararoudi M
    Front Oncol; 2022; 12():834002. PubMed ID: 35449580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
    Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
    Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
    Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
    Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR, CAR-T, and NK: Current applications and future perspectives.
    Khoshandam M; Soltaninejad H; Hamidieh AA; Hosseinkhani S
    Genes Dis; 2024 Jul; 11(4):101121. PubMed ID: 38545126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review.
    Balasubramanian A; Veluswami K; Rao S; Aggarwal S; Mani S
    Cureus; 2024 Jul; 16(7):e64324. PubMed ID: 39130943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Based Approaches for Cancer Immunotherapy.
    Malla RR; Middela K
    Crit Rev Oncog; 2023; 28(4):1-14. PubMed ID: 38050977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging CRISPR/Cas9 applications for T-cell gene editing.
    Preece R; Georgiadis C
    Emerg Top Life Sci; 2019 May; 3(3):261-275. PubMed ID: 33523139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems.
    Wang L; Chen Y; Liu X; Li Z; Dai X
    Front Oncol; 2021; 11():704999. PubMed ID: 35111663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
    Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
    J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.
    Ou X; Ma Q; Yin W; Ma X; He Z
    Front Cell Dev Biol; 2021; 9():674467. PubMed ID: 34095145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy.
    Ding S; Liu J; Han X; Tang M
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.
    Huang RS; Shih HA; Lai MC; Chang YJ; Lin S
    Front Immunol; 2020; 11():1008. PubMed ID: 32528479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.